Targeting SERCA2a as an innovative approach to the therapy of congestive heart failure

Medical Hypotheses

Volumn 68, Issue 5, 2007, Pages 1120-1125

  Ferrari, P ^a   Micheletti, R ^a   Valentini, G ^b   Bianchi, G ^c  

^a Prassis Sigma Tau Research Institute   (Italy)

^b Sigma Tau SpA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM SENSITIZER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISTAROXIME; NATRIURETIC FACTOR; SARCOPLASMIC RETICULUM CALCIUM PUMP 2A; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST;

ARTICLE; CALCIUM TRANSPORT; CHRONOTROPISM; CONGESTIVE HEART FAILURE; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEART CONTRACTION; HEART MUSCLE RELAXATION; HEART PROARRHYTHMIA; HUMAN; HYPOTENSION; INOTROPISM; MUSCLE CELL; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; QT PROLONGATION; SARCOPLASMIC RETICULUM; SIDE EFFECT;

CARDIOTONIC AGENTS; ETIOCHOLANOLONE; HEART FAILURE, CONGESTIVE; HUMANS; MODELS, CARDIOVASCULAR; MYOCARDIAL CONTRACTION; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 33847074126     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.08.045     Document Type: Article

References (37)

1. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
2. Stewart S., MacIntyre K., Hole D.J., Capewell S., and McMurray J.J. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Failure 3 (2001) 315-322
3. Baig M.K., Mahon N., McKenna W., et al. The pathophysiology of advanced heart failure. Am Heart J 135 Suppl. (1998) S216-S230
4. Nieminen M.S., and Harjola V.P. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 96 Suppl. 6A (2005) 5G-10G
5. Konstam M.A., and Mann D.L. Contemporary medical options for treating patients with heart failure. Circulation 105 (2002) 244-2246
6. Jain P., Massie B.M., Gattis W.A., Klein L., and Gheorghiade M. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. Am Heart J 145 Suppl. 2 (2003) S3-S17
7. Bayram M., De Luca L., Massie M.B., and Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 96 (2005) 47G-58G
8. Gheorghiade M., Gattis Stough W., Adams Jr. K.F., Jaffe A.S., Hasselblad V., and O'Connor C.M. The pilot randomized study of Nesiritide versus dobutamine in heart failure (PRESERVED-HF). Am J Cardiol 96 Suppl. 6A (2005) 18G-25G
9. Hasenfuss G., and Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol 34 (2002) 951-969
10. 2+ handling in heart failure. J Clin Invest 115 (2005) 556-564
11. Bers D.M. Excitation-contraction coupling and cardiac contractile force (2001), Kluwer Academic Publishers, Dordrecht
12. Marx S.O., Reiken S., Hisamatsu Y., et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101 (2000) 365-376
13. Meyer M., Schillinger W., Pieske B., et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92 (1995) 778-784
14. Schwinger R.H., Munch G., Bolck B., Karczewski P., Krause E.G., and Erdmann E. Reduced Ca(2+)-sensitivity of SERCA2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol 31 (1999) 479-491
15. O'Rourke B., Kass D.A., Tomaselli G.F., Kaab S., Tunin R., and Marban E. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. Circ Res 84 (1999) 562-570
16. 2+ exchanger expression and function in an arrhythmogenic rabbit model of heart failure. Circ Res 85 (1999) 1009-1019
17. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 99 (1999) 641-648
18. Weber C.R., Piacentino III V., Houser S.R., and Bers D.M. Dynamic regulation of sodium/calcium exchange function in human heart failure. Circulation 108 (2003) 2224-2229
19. Muller O.J., Lange M., Rattunde H., et al. Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload. Cardiovasc Res 59 (2003) 380-389
20. Freeman K., Lerman I., Kranias E.G., et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 107 (2001) 967-974
21. Iwanaga Y., Hoshijima M., Gu Y., et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 113 (2004) 727-736
22. McMurray J., and Pfeffer M.A. New therapeutic options in congestive heart failure: Part I. Circulation 105 (2002) 2099-2106
23. Cuffe M.S., Califf R.M., Adams Jr. K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
24. Felker G.M., and O'Connor C.M. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 142 (2001) 393-401
25. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. New Engl J Med 1997;336:525-33.
26. + pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride]. J Pharmacol Exp Ther 313 (2005) 207-215
27. Micheletti R., Mattera G.G., Rocchetti M., et al. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther 303 (2002) 592-600
28. Micheletti R, Palazzo P, Barassi P, et al. Istaroxime, a stimulator of SERCA2a activity, as a novel therapeutic approach to heart failure. Am J Cardiol, in press.
29. McGarry S.J., and Williams A.J. Digoxin activates sarcoplasmic reticulum Ca(2+)-release channels: a possible role in cardiac inotropy. Br J Pharmacol 108 (1993) 1043-1050
30. Sagawa T., Sagawa K., Kelly J.E., Tsushima R.G., and Wasserstrom J.A. Activation of cardiac ryanodine receptors by cardiac glycosides. Am J Physiol 282 (2002) H1118-H1126
31. Mattera GG, Lo Giudice P, Loi FMP, et al. Istaroxime: a safe new lusi-inotropic agent for heart failure. Am J Cardiol, in press.
32. Sabbah H, Imai M, Cowart D, Amato A, Carminati P, Gheorghiade M. Hemodynamic properties of a new generation positive lusi-inotropic agent for the acute treatment of advanced heart failure. Am J Cardiol, in press.
33. Adamson P.B., Vanoli E., Mattera G.G., et al. Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure. J Cardiovasc Pharmacol 42 (2003) 169-173
34. Mattera G.G., Loi F., Botarelli M., et al. Hemodynamic effect and safety of PST2744 during acute myocardial ischemia and reperfusion in anesthetized dogs. Pharmacologist 44 Suppl. 1 (2002) A18-A23
35. Mattera G.G., Loi F.M., Vanoli E., et al. PST2744 improves systo-diastolic contractility and reduces myocardial stunning in acute high after-load ischemia/reperfusion canine model. J Cardiac Failure 9 Suppl. (2003) 234
36. PST2744: invasive electrophysiology in anesthetized dogs. Study PST 2744-SFG 00-14, Sigma-Tau internal data report v.2.
37. Ghali J, Smith W, Torre-Amione G, et al. A Phase I-II dose escalating study evaluating the safety and tolerability of PST 2744 and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure and reduced systolic function. Am J Cardiol, in press.